Rush Salicylc Acid Complexion Pads

Description

Salicylic acid is the active ingredient in the complexion pads, designed specifically for oily to combination skin types. Each container includes 60 pads, which serve as anti-imperfection tampons. The formulation leverages the properties of salicylic acid to target blemishes and promote clearer skin.

Uses and Indications

This drug is indicated for the management of acne. It effectively reduces the severity of oiliness and smooths the complexion. Additionally, it helps prevent the development of new acne blemishes.

Dosage and Administration

Healthcare professionals should ensure that the skin is thoroughly cleaned prior to the application of this product. A thin layer should be applied to the entire affected area, followed by thorough rinsing.

Initial treatment should begin with one application daily to minimize the risk of excessive drying of the skin. Based on the patient's response and as directed by a physician, the frequency of application may be gradually increased to two or three times daily.

In cases where bothersome dryness or peeling occurs, it is advisable to reduce the frequency of application to once daily or every other day to maintain skin integrity and comfort.

Contraindications

The product should not be applied directly to the skin for prolonged periods. Leaving the pad on the skin may lead to adverse effects. No other contraindications have been identified.

Warnings and Precautions

This product is intended for external use only. Healthcare professionals should advise patients against the concurrent use of other topical acne medications, as this may exacerbate skin dryness or irritation. In such cases, it is recommended that only one medication be utilized unless otherwise directed by a healthcare provider.

To ensure safety, this product must be kept out of reach of children. Patients should be cautioned to avoid contact with the eyes. In the event of accidental contact, it is imperative to rinse the affected area thoroughly with water.

Patients should not leave the pad on the skin for extended periods. It is important to note that this product contains a beta hydroxy acid (BHA), which may heighten the skin's sensitivity to sunlight, increasing the risk of sunburn. Therefore, it is essential to recommend the use of sunscreen, protective clothing, and to limit sun exposure during the use of this product and for at least one week following its discontinuation.

Side Effects

Patients using this product should be aware of several important warnings and precautions. This product is intended for external use only. The concurrent use of other topical acne medications may lead to increased dryness or irritation of the skin. In such cases, it is advised that only one medication be used unless directed by a healthcare professional.

While using this product, patients should avoid contact with the eyes. In the event of contact, it is essential to rinse the area thoroughly with water. Additionally, patients should not leave the pad on the skin for extended periods.

It is important to note that this product contains a beta hydroxy acid (BHA), which may heighten the skin's sensitivity to sunlight, increasing the risk of sunburn. Therefore, patients are advised to use sunscreen, wear protective clothing, and limit sun exposure during the use of this product and for at least one week following its discontinuation.

Drug Interactions

Concurrent use of other topical acne medications with this product may lead to increased dryness or irritation of the skin. In such cases, it is advisable to limit the use to one medication at a time unless otherwise directed by a healthcare professional. Monitoring for signs of excessive dryness or irritation is recommended to ensure patient comfort and skin health.

Packaging & NDC

Below are the non-prescription pack sizes of Rush Salicylc Acid Complexion Pads (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. Safety and efficacy have not been established in pediatric populations, and specific dosing recommendations for children are not provided. Caution is advised when administering this medication in settings where children may have access.

Geriatric Use

There is no specific information regarding the use of Rush Salicylic Acid Complexion Pads in geriatric patients. The prescribing information does not provide guidance on dosage adjustments, safety concerns, or special precautions that may be necessary for elderly patients. Therefore, healthcare providers should exercise caution and consider individual patient factors when prescribing this product to geriatric patients, as the absence of specific data necessitates careful monitoring and assessment of treatment outcomes in this population.

Pregnancy

The product has not specified any information regarding its use during pregnancy, including safety concerns, dosage modifications, or special precautions. There are no explicit statements regarding contraindications in pregnancy. Additionally, the prescribing information does not mention any specific risks to the fetus or maternal health during pregnancy. Consequently, no dosage modifications for pregnant individuals are provided, and no special precautions regarding use during pregnancy are included in the text. Healthcare professionals should consider these factors when prescribing this product to pregnant patients or women of childbearing potential.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there are no statements concerning the potential for excretion in breast milk or any associated risks to breastfed infants during lactation.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion or misuse. It is important to emphasize the necessity of avoiding contact with the eyes. In the event that contact does occur, patients should be instructed to rinse their eyes thoroughly with water to mitigate any potential irritation.

Additionally, healthcare providers should inform patients not to leave the pad on the skin for extended periods. This guidance is crucial to ensure the safe and effective use of the product while minimizing the risk of adverse effects.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It should be stored at a controlled room temperature of 20° to 25°C (68° to 77°F). Care should be taken to ensure that the product is kept within this temperature range to maintain its integrity and efficacy.

Additional Clinical Information

The product is administered topically, with a recommended application of a thin layer over the entire affected area, followed by thorough rinsing one to three times daily. Patients should begin with one application daily and may gradually increase to two or three times daily as needed or directed by a clinician. If dryness or peeling becomes bothersome, patients are advised to reduce the frequency to once a day or every other day.

Clinicians should counsel patients to avoid contact with the eyes, and in the event of contact, to rinse thoroughly with water. It is important to note that the product contains a beta hydroxy acid (BHA), which may heighten skin sensitivity to sunlight, increasing the risk of sunburn. Patients should be advised to use sunscreen, wear protective clothing, and limit sun exposure during treatment and for one week following discontinuation.

Drug Information (PDF)

This file contains official product information for Rush Salicylc Acid Complexion Pads, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)